Johannes malena (24 risultati)

Condizione: As New. Unread book in perfect condition.

Condizione: New.

Paperback. Condizione: new. Paperback. Raising costs, ever-increasing regulatory hurdles, and mounting difficulties in finding the next blockbuster drug are just a few of the challenges Big Pharma currently has to face for its research and development process, the heart of its risky business. Big Data claims to be full of insights that Big Pharma need to find a way of harvesting, which could lead to new compounds. Academics, Big Data start-ups, and pharmaceutical companies have focused their research efforts on analytic tools and data technologies to store, collect, analyse, and extract these insights from massive data sets. However, the key question is whether the Big Data hype really does have the claimed accelerating effect on the complex research and development process or if it actually creates another hurdle for Big Pharma innovation. Malena Johannes' timely book sheds light on this question by examining the top 5 pharmaceutical companies and provides an overview on the status quo of Big Data applications within the pharmaceutical industry. Shipping may be from multiple locations in the US or from the UK, depending on stock availability.…

PAP. Condizione: New. New Book. Shipped from UK. Established seller since 2000.

PAP. Condizione: New. New Book. Shipped from UK. Established seller since 2000.

Condizione: New. pp. 132.

Condizione: New.

Condizione: New. pp. 132.

Condizione: New. 2016. New. paperback. . . . . .

Condizione: New. pp. 132.

Condizione: New. In English.

Condizione: New. 2016. New. paperback. . . . . . Books ship from the US and Ireland.

Condizione: New.

Condizione: As New. Unread book in perfect condition.

Paperback. Condizione: new. Paperback. Raising costs, ever-increasing regulatory hurdles, and mounting difficulties in finding the next blockbuster drug are just a few of the challenges Big Pharma currently has to face for its research and development process, the heart of its risky business. Big Data claims to be full of insights that Big Pharma need to find a way of harvesting, which could lead to new compounds. Academics, Big Data start-ups, and pharmaceutical companies have focused their research efforts on analytic tools and data technologies to store, collect, analyse, and extract these insights from massive data sets. However, the key question is whether the Big Data hype really does have the claimed accelerating effect on the complex research and development process or if it actually creates another hurdle for Big Pharma innovation. Malena Johannes' timely book sheds light on this question by examining the top 5 pharmaceutical companies and provides an overview on the status quo of Big Data applications within the pharmaceutical industry. Shipping may be from our Sydney, NSW warehouse or from our UK or US warehouse, depending on stock availability.…

Paperback. Condizione: New. New Book, Direct from Publisher.

Taschenbuch. Condizione: Neu. Big Data for Big Pharma | Malena Johannes | Taschenbuch | 130 S. | Englisch | 2016 | ibidem-Verlag | EAN 9783838209425 | Verantwortliche Person für die EU: ibidem-Verlag, Leuschnerstr. 40, 30457 Hannover, info[at]ibidem[dot]eu | Anbieter: preigu.

Condizione: Sehr gut. Zustand: Sehr gut | Sprache: Englisch | Produktart: Bücher | Raising costs, ever-increasing regulatory hurdles, and mounting difficulties in finding the next blockbuster drug are just a few of the challenges Big Pharma currently has to face for its research and development process, the heart of its risky business. Big Data claims to be full of insights that Big Pharma need to find a way of harvesting, which could lead to new compounds. Academics, Big Data start-ups, and pharmaceutical companies have focused their research efforts on analytic tools and data technologies to store, collect, analyse, and extract these insights from massive data sets. However, the key question is whether the Big Data hype really does have the claimed accelerating effect on the complex research and development process or if it actually creates another hurdle for Big Pharma innovation.Malena Johannes' timely book sheds light on this question by examining the top 5 pharmaceutical companies and provides an overview on the status quo of Big Data applications within the pharmaceutical industry.…

PAP. Condizione: New. New Book. Shipped from UK. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000.

PAP. Condizione: New. New Book. Delivered from our UK warehouse in 4 to 14 business days. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000.

Taschenbuch. Condizione: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Raising costs, ever-increasing regulatory hurdles, and mounting difficulties in finding the next blockbuster drug are just a few of the challenges Big Pharma currently has to face for its research and development process, the heart of its risky business. Big Data claims to be full of insights that Big Pharma need to find a way of harvesting, which could lead to new compounds. Academics, Big Data start-ups, and pharmaceutical companies have focused their research efforts on analytic tools and data technologies to store, collect, analyse, and extract these insights from massive data sets. However, the key question is whether the Big Data hype really does have the claimed accelerating effect on the complex research and development process or if it actually creates another hurdle for Big Pharma innovation. Malena Johannes' timely book sheds light on this question by examining the top 5 pharmaceutical companies and provides an overview on the status quo of Big Data applications within the pharmaceutical industry. 132 pp. Englisch.…

Condizione: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Raising costs, ever-increasing regulatory hurdles, and mounting difficulties in finding the next blockbuster drug are just a few of the challenges Big Pharma currently has to face for its research and development process, the heart of its risky business. .…

Taschenbuch. Condizione: Neu. This item is printed on demand - Print on Demand Titel. Neuware -Raising costs, ever-increasing regulatory hurdles, and mounting difficulties in finding the next blockbuster drug are just a few of the challenges Big Pharma currently has to face for its research and development process, the heart of its risky business.Big Data claims to be full of insights that Big Pharma need to find a way of harvesting, which could lead to new compounds. Academics, Big Data start-ups, and pharmaceutical companies have focused their research efforts on analytic tools and data technologies to store, collect, analyse, and extract these insights from massive data sets. However, the key question is whether the Big Data hype really does have the claimed accelerating effect on the complex research and development process or if it actually creates another hurdle for Big Pharma innovation.Malena Johannes' timely book sheds light on this question by examining the top 5 pharmaceutical companies and provides an overview on the status quo of Big Data applications within the pharmaceutical industry.Books on Demand GmbH, Überseering 33, 22297 Hamburg 130 pp. Englisch.…

Taschenbuch. Condizione: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - Raising costs, ever-increasing regulatory hurdles, and mounting difficulties in finding the next blockbuster drug are just a few of the challenges Big Pharma currently has to face for its research and development process, the heart of its risky business. Big Data claims to be full of insights that Big Pharma need to find a way of harvesting, which could lead to new compounds. Academics, Big Data start-ups, and pharmaceutical companies have focused their research efforts on analytic tools and data technologies to store, collect, analyse, and extract these insights from massive data sets. However, the key question is whether the Big Data hype really does have the claimed accelerating effect on the complex research and development process or if it actually creates another hurdle for Big Pharma innovation. Malena Johannes' timely book sheds light on this question by examining the top 5 pharmaceutical companies and provides an overview on the status quo of Big Data applications within the pharmaceutical industry.…